[Reuters] – AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96 percent of patients had no detectable levels of the virus after 12 weeks. The trial is being watched closely …
Read more on this.
AbbVie Inc. (ABBV), with a current value of … [visit site to read more]
Similar posts:- Market Update on McDonalds Corporation (NYSE:MCD) – McDonald’s helps workers get food stamps
- Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review
- Chevron goes to trial in New York over $18 billion Ecuador award – Chevron Corporation (NYSE:CVX)